Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bernard Douglas

Pediatrics Omaha, NE Medical Doctor

NPI 1417062399 CMS profile 18801

16128 Davenport St, Omaha, NE 68118

Open in the dashboard

General payments

$6,154

349 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bernard Douglas of Omaha, NE is reported in the CMS Open Payments database as having received $6,154 across 349 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $935 47
2024 General $1,339 69
2023 General $872 49
2022 General $1,031 62
2021 General $819 56
2020 General $530 31
2019 General $629 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bernard Douglas
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Bernard Douglas were reported at $935. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Bernard Douglas Pediatrics median Middle half National median
2019 $629 $86 $31–$183 $163
2020 $530 $49 $22–$110 $114
2021 $819 $68 $27–$158 $132
2022 $1,031 $77 $30–$173 $149
2023 $872 $88 $33–$190 $160
2024 $1,339 $94 $34–$206 $164
2025 $935 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $895 43 payments
  2. CSL Behring $888 54 payments
  3. Grifols USA, LLC $734 38 payments
  4. AstraZeneca Pharmaceuticals LP $588 26 payments
  5. Pharming Healthcare, Inc. $479 29 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $469 35 payments
  7. Genentech USA, Inc. $319 14 payments
  8. BioCryst US Sales Co., LLC $305 17 payments
  9. Amgen Inc. $225 12 payments
  10. kaleo, Inc. $164 12 payments
  11. Other $1,087 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,154 349 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $780 38 payments
  2. Xembify $541 27 payments
  3. RUCONEST $479 29 payments
  4. Hizentra $465 23 payments
  5. TAKHZYRO $363 31 payments
  6. Haegarda $328 24 payments
  7. Xolair $319 14 payments
  8. Orladeyo $305 17 payments
  9. SYMBICORT $286 6 payments
  10. FASENRA $252 3 payments
  11. Other $2,562 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record